Nagi S. El-Saghir, MD, FACP, FASCO, discusses the inception of the phase 2 RIGHT Choice trial of ribociclib plus ET.
Nagi S. El-Saghir, MD, FACP, FASCO
Advertisement
Nagi S. El-Saghir, MD, FACP, FASCO is Professor of Clinical Medicine, Head of the Division of Hematology Oncology, Department of Internal Medicine and Director of the Breast Center of Excellence, Naef K Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
Articles by Nagi S. El-Saghir, MD, FACP, FASCO
Nagi S. El-Saghir, MD, FACP, FASCO, discusses the clinical implications of the phase 2 RIGHT Choice trial.
Nagi S. El-Saghir, MD, FACP, FASCO, discusses ribociclib plus endocrine therapy in premenopausal HR-positive breast cancer by liver metastases status.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL
5